Shots:
- The US FDA has granted Breakthrough Device Designation to the urine-based Multi-Cancer Early Detection (MCED) test
- The non-invasive platform analyzes volatile organic compounds (VOCs) using spectroscopy & machine learning to detect multiple cancers from a single urine sample
- The test provides an alternative to blood-based screening, supporting scalable population screening, while the designation enables TOBY to expand adoption of accessible early cancer detection solutions
Ref: PRnewswire | Image: Toby | Press Release
Related News: QIAGEN Launches QIAstat-Dx BCID GPF Plus AMR Panel for Bloodstream Infection Syndromic Testing
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
